SEngine Precision Medicine, Inc. — Form D/A
SEngine Precision Medicine, Inc. of SEATTLE, WA, a company, filed a Form D amendment with the SEC on 2019-10-09. The offering totals $13.6M, of which $8.6M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2019-10-09
- Form: D/A
- Accession: 0001752445-19-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $13.6M
- Amount sold: $8.6M
- Remaining: $4.9M
- Investors: 40
- Date of first sale: 2018-08-29
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-321149
Issuer
- Name: SEngine Precision Medicine, Inc.
- CIK: 0001752445
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2015
- Address: 401 TERRY AVE N., SEATTLE, WA, 98109
- Phone: 206-732-2165
Officers, directors & promoters (12)
| Name | Role | Location |
|---|
| Jesse Ferrer | Director | Seattle, WA |
| Lee Hartwell | Director | Seattle, WA |
| Ulrich Mueller | Executive Officer | Seattle, WA |
| Tom Neary | Executive Officer | Seattle, WA |
| Tony Hsu | Executive Officer | El Segundo, CA |
| Christopher Kemp | Executive Officer | Seatttle, WA |
| Christopher Kemp | Promoter | Seatttle, WA |
| Pablo Prichard | Director | Seattle, WA |
| Elliott Burkland | Director | Seattle, WA |
| Carla Grandori | Director | Seattle, WA |
| Carla Grandori | Executive Officer | Seattle, WA |
| Carla Grandori | Promoter | Seattle, WA |
Other filings by this issuer (2)
More